Serum S100B levels may be associated with cerebral infarction: a meta-analysis

• To explore the association of serum S100B levels with diagnosis and prognosis of CI
• S100B serum levels could be regarded as a biomarker of CI.
• S100B could contribute aide into the diagnosis and prognosis of CI.

ObjectiveThe aim of this paper is to explore the potential association of serum human soluble protein-100B protein (S100B) levels with the diagnosis and prognosis of cerebral infarction (CI).MethodsPotential relevant studies were searched for in PubMed, Springerlink, Wiley, EBSCO, Ovid, Web of Science, Wanfang databases, China National Knowledge Infrastructure (CNKI) databases and VIP databases. Two investigators extracted data and assessed studies independently. Statistical analyses were carried out with the version 12.0 STATA statistical software.ResultsA total of 10 case–control studies that assessed the correlation of S100B serum level with CI, including 1211 subjects (patients = 773, healthy controls = 438) were included. The results showed that S100B serum levels in CI victims were significantly higher compared with those of the control group. According to the subgroup analysis by ethnicity, S100B serum level in CI victims was statistically significant in Asians and the control group, but no statistical significance was found in Caucasians. An additional subgroup analysis was carried out based on sample size, revealing that the S100B serum levels in CI victims in small samples were of statistical significance; however, no statistical significance was discovered in large samples.ConclusionsElevator S100B serum levels might be negatively correlated with CI, suggesting that higher serum levels of S100B could lead to more serious condition and worse prognoses for CI patients. Therefore, S100B serum levels could be regarded as a biomarker for CI, and furthermore, S100B could aide in the diagnosis and prognosis of CI.